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Abstract
Objective—To characterize puberty in girls with Turner syndrome (TS) and determine whether 
specific patient characteristics are associated with the timing of menarche. We also sought to 
compare spontaneous versus induced puberty in these patients.
Methods—Medical records of girls followed in our Pediatric Endocrine clinic for TS from 2007 
to 2015 were reviewed.
Results—Fifty-three girls were included, of whom 10 (19%) achieved menarche spontaneously 
and 43 (81%) received hormone replacement therapy (HRT). Of girls receiving HRT, a younger 
age at estrogen initiation correlated with a longer time to menarche (P = .02), and a mosaic 
karyotype was associated with a shorter time to menarche (P = .02), whereas no relationship was 
seen for body mass index, estrogen regimen, or maternal age at menarche. Nineteen girls (44%) 
receiving HRT had bleeding on estrogen alone at a wide dose range and were more likely to be on 
transdermal than oral preparations (P = .01). Girls with spontaneous puberty achieved menarche at 
a younger age (P<.01) and were more likely to have mosaic TS (P = .02).
Conclusion—Significant variability in the timing of menarche exists among girls with TS. 
However, age at pubertal induction and karyotype were significantly correlated with age at 
menarche in our patients. A wide range of estrogen doses is seen in girls who bleed prior to 
progesterone, suggesting extreme variability in estrogen sensitivity among patients with TS. Girls 
achieving spontaneous menarche are younger and more likely to have a mosaic karyotype than 
those with induced menarche. Large-scale prospective studies are needed to confirm these results.
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Turner syndrome (TS) is one of the most common chromosomal abnormalities in females, 
with an annual incidence of 1 in 2,500 live births (1). First described in 1938, the most 
common phenotypic features of TS are short stature and primary ovarian failure (2). On 
average, 50% of girls with TS are monosomy X, whereas the remainder have a variety of 
karyotypes, including mosaicism and partial deletions of one X chromosome (3). Primary 
ovarian failure occurs in >80% of girls with TS, and estrogen therapy is required for pubertal 
development with the subsequent addition of progesterone to induce menses (4). While 
standardized algorithms for hormone replacement therapy (HRT) in girls with TS are 
currently lacking, the goal is to simulate the timing and tempo of normal puberty as much as 
possible in order to achieve optimal psychosexual outcomes (1,5). It is currently unknown 
whether individual patient or treatment characteristics influence the time from the initiation 
of estrogen to menarche in these patients. Furthermore, minimal information exists 
regarding how girls with TS who go through puberty on their own and achieve spontaneous 
menarche differ from those in whom menarche is induced. Thus, the objectives of this study 
were to characterize puberty in a cohort of girls with TS and to compare those with 
spontaneous versus induced puberty. We also investigated whether individual factors were 
related to the timing of menarche in girls with TS who were treated with HRT.
METHODS
After ethical approval from the Indiana University institutional review board (IRB), medical 
records of girls followed for TS in the pediatric endocrine clinic at Riley Hospital for 
Children between January 2007 and May 2015 were reviewed. Records were initially 
identified using International Classification of Diseases, ninth revision (ICD-9) code 758.6, 
which includes TS, gonadal dysgenesis, and ovarian dysgenesis. As no personal identifying 
patient information was recorded, informed consent was not required by the IRB and a 
waiver was granted. Historical information collected included age at diagnosis of TS, 
additional medical problems, karyotype, maternal age at menarche, patient age at menarche, 
and whether puberty was spontaneous or induced. For girls with induced puberty, additional 
variables analyzed included age at the initiation of estrogen as well as the dose, formulation, 
and escalation schedule used, and whether bleeding occurred prior to the addition of 
progesterone. Body mass index (BMI) at the time that initial breast development was 
documented (in girls with spontaneous puberty), and at initiation of estrogen (in girls with 
induced puberty) and at menarche (in both) was also recorded.
Statistical Analysis
Descriptive statistics were calculated for subjects with spontaneous menarche and those with 
induced menarche. BMI Z-scores were derived using a web-based BMI calculator based on 
the Clinical Growth Charts of the Centers for Disease Control and Prevention, published in 
2000 (6). Subjects with spontaneous menarche were compared to those with induced 
menarche. Data are expressed as mean and standard deviation for continuous variables and 
frequencies with percentages for categorical variables. Student’s t tests were used to 
determine P values for continuous variables, and Fisher’s exact tests were used for 
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categorical variables. Subjects who received HRT for pubertal induction were analyzed 
based on whether they experienced menarche prior to initiation of progesterone. Parameter 
estimates were slope and standard error for regression analyses for continuous variables and 
odds ratios with 95% confidence intervals for logistic regression analyses for categorical 
variables. Calculations were performed using SAS version 9.4 (SAS Institute, Cary, NC) and 
SPSS Statistics version 23.0 (IBM Corp, Armonk, NY). The α level was set at .05, and P 
values ≤.05 were considered significant.
RESULTS
Of 191 charts initially identified by ICD-9 code 758.6, 112 were excluded after manual chart 
review revealed a diagnosis other than TS, leaving 79 evaluable patients with TS. Thirty-six 
of these were excluded because the girls had not yet completed puberty. The remaining 53 
patients were included in the analysis. Of these, 43 girls (81%) had induced menarche, and 
10 (19%) had spontaneous menarche. The average age of diagnosis of TS was 6.4 ± 5.6 
years (range, prenatally to 16.8 years). The diagnosis of TS was made prenatally in 4 
patients (7.8%) and postnatally in the remaining 49 (92.2%). A 45,X karyotype was found in 
32.1% of patients, while the remaining 62.3% had a mosaic karyotype. Two of the patients 
with a prenatal diagnosis were 45,X, while the other 2 patients had mosaic karyotypes. Over 
half the patients (54.7%) had additional medical diagnoses, including hypothyroidism, 
hearing loss, developmental delay, and attention deficit hyperactivity disorder. Maternal age 
at menarche was 13.2 ± 1.4 years (range, 11 to 17 years). A summary of baseline patient 
characteristics is provided in Table 1.
For girls with primary ovarian failure, the mean age at estrogen initiation was 13.9 ± 1.9 
years (range, 11.3 to 19 years), and the mean age at menarche was 15.7 ± 1.9 years (range, 
11 to 19.5 years). None had initial pubertal development that subsequently arrested. The 
mean BMI Z-score was 0.65 ± 1.15 at estrogen initiation and 0.80 ± 1.01 at menarche. The 
initial estrogen dose ranged from 0.00175 mg transdermal to 0.625 mg oral, and the estrogen 
dose at menarche ranged from 0.025 mg transdermal to 2 mg oral. Specific estrogen 
formulations used included transdermal ethinyl estradiol, oral conjugated estrogen, and oral 
ethinyl estradiol. The average time from estrogen initiation to menarche was 2.4 ± 1.1 years 
(range, 0.5 to 4.75 years). As shown in Figure 1, a younger age at estrogen initiation 
correlated with a longer time to menarche (P = .02). A mosaic karyotype correlated with a 
shorter time to menarche (P = .02), whereas no relationship was seen for BMI Z-score, 
estrogen route or dose, maternal age at menarche, or prenatal versus postnatal diagnosis. The 
relationship between patient variables and time to menarche is seen in Table 2.
Within the group that underwent induced menarche, 19 girls (44.2%) had bleeding on 
estrogen alone, and 24 (55.8%) were treated with progesterone prior to experiencing 
menarche. A greater proportion of girls who bled on estrogen alone were treated with 
transdermal estrogen (P = .01). No other differences in regards to individual patient 
characteristics were seen between these girls and girls treated with progesterone to 
precipitate menarche, as shown in Table 3.
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Girls who completed puberty spontaneously were significantly younger at menarche than 
those who required pubertal induction (P<.01). This finding is in line with results from a 
2014 study assessing pubertal timing in girls with TS and is likely influenced by the timing 
of puberty induction (7). In our cohort, girls with spontaneous menarche were also 
significantly more likely to have mosaic karyotypes than girls with ovarian failure (P = .02). 
These results are seen in Figures 2 and 3.
DISCUSSION
Estrogen therapy is required for pubertal development and progression in girls with TS and 
primary ovarian failure. Although clinical practice guidelines recommend estrogen initiation 
in a manner that mimics the physiologic progression of normal puberty (1), the optimal age 
and developmental stage at which to begin pubertal induction in girls with TS have not been 
defined, and clinical practice varies widely (8). Additionally, it is unknown whether the dose 
or form of estrogen administration has any bearing on the timing of menarche or tempo of 
pubertal development in this patient population.
In girls without TS, the average age at the onset of puberty has traditionally been thought to 
be 10.2 years, with menarche occurring approximately 2.3 years on average after initial 
breast development (9). Studies have demonstrated that the typical tempo of puberty in 
female adolescents is related to the age of onset, with a longer time to menarche in girls who 
enter puberty at an earlier age. An analysis of 163 girls subgrouped by age of puberty onset 
found that duration of puberty was inversely proportional to the age of onset (10). This is 
similar to our results, which identified that a younger age at estrogen initiation was 
associated with a longer time to menarche in our group of patients with TS who required 
pubertal induction. Our results also demonstrated a shorter time from induction to menarche 
in girls with mosaic karyotypes. It has been demonstrated that prepubertal girls with TS have 
significantly lower serum estradiol levels than girls without TS, even before the onset of 
puberty (11). It is not known, however, whether estradiol levels of girls with TS and ovarian 
failure vary in relation to karyotype. The current guidelines do not recommend routine 
measurement of estradiol levels in pediatric patients with TS, and therefore, these were not 
regularly obtained in our cohort. It may be that girls with mosaic karyotypes have higher 
endogenous estradiol levels and thus require less exogenous estrogen to initiate and 
complete pubertal development. As more sensitive estradiol assays are developed, additional 
research in this area could further explore this hypothesis. Another potential physiologic 
explanation for this finding could be related to greater tissue sensitivity to estrogen in girls 
with a mosaic versus monosomy X karyotype. However, data to support this hypothesis are 
similarly lacking, and further studies are needed.
Interestingly, we observed a wide range of estrogen doses at the time of menarche in our 
patients receiving HRT. Some girls in our study had vaginal bleeding on doses of estrogen as 
low as 0.025 mg transdermal, while other patients required estrogen doses as high as 2 mg 
oral before menarche occurred. Another interesting finding was that 44% of patients with 
induced puberty had bleeding on estrogen therapy alone on a wide range of doses, indicating 
extreme variability in estrogen sensitivity among these patients.
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Girls who bled on estrogen alone prior to the addition of progesterone for cycling were 
significantly more likely to have been treated with transdermal, rather than oral, estrogen. 
This is likely related to physiologic differences between transdermal versus oral 
formulations of estrogen. In 2013, a randomized trial comparing transdermal to oral estrogen 
was conducted in 40 adolescent girls with TS to determine whether the mode of estrogen 
delivery affected metabolic markers (12). Although individuals treated with oral estrogen 
were noted to have higher levels of estrone, estrone sulfate, and sex hormone–binding 
globulin, levels of free estradiol were similar between the two groups. Moreover, the girls 
treated with transdermal estrogen were more likely to have levels of both estrogen 
precursors and estradiol similar to those in age- and sex-matched girls without TS, 
suggesting that transdermal estrogen delivers more physiologic effects.
Another rationale for using transdermal rather than oral estrogen therapy for pubertal 
induction in girls with TS comes from a multicenter study performed in Sweden. In this 
study, 54 girls with hypogonadism were treated with escalating doses of transdermal 
estrogen ranging from 0.05 to 0.15 μg/kg, administered nocturnally only. Multiple sequential 
estradiol levels were measured and compared to those of girls without hypogonadism in 
similar stages of pubertal development (13). A subgroup analysis was performed in the 31 
girls with TS which demonstrated a linear relationship between estrogen dose and serum 
estradiol levels, with lower starting doses more closely resembling estradiol levels in normal 
girls in corresponding stages of puberty. Transdermal estrogen has also been linked to higher 
bone mineral density and increased uterine volumes compared with oral conjugated estrogen 
in a pilot study of girls with TS (14). Given the cumulative evidence supporting preferential 
use of the transdermal route, it is not surprising that all but one of the girls in our study 
treated from 2009 on have been treated with this modality.
In our study, nearly 20% of girls with TS entered puberty and achieved menarche 
spontaneously, without the need for exogenous HRT. All of these girls had mosaic 
karyotypes. When evaluating the subgroup of girls with mosaic karyotypes, nearly 38% 
experienced spontaneous menarche. This is a higher proportion than that seen in a 
previously published assessment of 40 patients with mosaic TS, in which 15% had 
spontaneous menarche (15). Molecular-cytogenic analyses were performed to determine the 
degree of X chromosome mosaicism, and women with mosaicism of at least 10% were 
found to be significantly more likely to undergo spontaneous menarche than those with 
lower levels. Another larger study of 522 women with TS reported a spontaneous menarche 
rate of 16%, with 70% of those women having mosaic karyotypes (4). Taken together, these 
studies indicate that when counseling families and patients with TS, a spontaneous menarche 
rate of 15 to 20% can be reasonably estimated, with potentially higher rates in patients with 
mosaic karyotypes.
Several strengths of our study include the relatively large number of patients with TS, the 
availability of long-term clinical and laboratory assessments, and clear documentation of 
estrogen doses and adjustments. Our study also has several limitations. As this was a 
retrospective study, we were not able to control for potential confounding factors, including 
variable patient follow-up, patient adherence to therapy, and the multitude of disparate 
treatment regimens used, making it difficult to compare girls to each other. Although the R2 
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was significant, the value of 0.143 suggests that there are other variables affecting timing of 
menarche in our patient population. The additional factors mentioned above likely contribute 
to the time span from puberty induction to menarche and should be further evaluated. 
Decisions regarding the timing and pace of pubertal induction in girls with TS are complex 
and must take into consideration numerous variables, including height potential and patient 
preferences concerning prioritization of height versus feminization. To our knowledge, ours 
is the first study to systematically characterize puberty in girls with TS, and our results may 
facilitate management decisions, especially in those with mosaic karyotypes.
CONCLUSION
Our findings emphasize the broad spectrum of pubertal development in girls with TS, 
ranging from complete ovarian failure to spontaneous puberty and menarche. They also 
confirm that girls with mosaic TS are significantly more likely to undergo spontaneous 
menarche than those with 45,X karyotypes. Furthermore, the wide range of estrogen doses 
being prescribed at the time of menarche in girls with induced puberty emphasizes the 
extreme variability in estrogen sensitivity in these patients. This suggests that estrogen 
titration should be guided in part by individual responses and evaluated on an ongoing basis 
in conjunction with patients and families over time. Our results should help to inform 
decisions regarding timing of estrogen initiation and provide important prognostic 
information for families and providers who care for girls with TS.
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Correlation between age at induction of puberty and time to menarche.
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Side-by-side comparison of girls with induced and spontaneous menarche by age at 
menarche, maternal age at menarche, and time from induction of puberty to menarche.
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Comparison of karyotype in girls with induced versus spontaneous menarche.
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Table 1
Baseline Patient Characteristics
Patient population (N) 53
Age at diagnosis (years, ±SD) 6.4 ± 5.6
 Age range, years 0–16.8
 Prenatal (n, %) 4 (7.8)
 Postnatal (n, %) 49 (92.2)
Maternal age at menarche (years, ±SD) 13.2 ± 1.4
 Age range, years 11–17
45,X (n, %) 17 (32.1)
Mosaic (n, %) 33 (62.3)
Additional diagnoses (n, %) 24 (45.3)
Induced puberty (n, %) 43 (81)
Spontaneous menarche (n, %) 10 (19)
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Table 2
Relationships Between Patient Variables and Time to Menarche
Slope (standard error) P value
Age at initiation of estrogen −0.20 (0.08)
.02a
Mother’s age at menarche −0.13 (0.15) .39
BMI at menarche −0.00 (0.03) .91
BMI Z-score at menarche −0.06 (0.18) .73
Karyotype
 Mosaic 1.82 (0.89)
.02a
 Mosaic with Y 3.20 (1.57)
 Structural abnormality 2.05 (0.72)
 45,X 2.75 (0.95)
Estrogen regimen
 Oral 2.42 (0.82) .8
 Patch 2.33 (1.21)
Timing of TS diagnosis 0.06 (0.56)
 Prenatally .92
 Postnatally
Abbreviations: BMI = body mass index; TS = Turner syndrome.
aSignificant difference.
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Table 3
Predictors of Bleeding on Estrogen Alone
“Yes” bleeding estrogen only (n = 19) “No” bleeding estrogen only (n = 24) P value
Age at initiation/estrogen, years 13.5 (1.8) 14.2 (1.9) .23
Mother’s age at menarche, years 13.2 (1.4) 13.4 (1.4) .69
BMI at menarche, kg/m2 24.5 (4.7) 27.1 (6.9) .14
BMI Z-score at menarche 0.79 (0.90) 1.00 (0.98) .47
Karyotype (2 groups) (n, %)
 Mosaic 12 (66.7) 12 (52.2) .52
 45,X 6 (33.3) 11 (47.8)
Estrogen regimen (n, %)
 Oral 3 (15.8) 13 (54.2)
 Patch 16 (84.2) 11 (45.8)
.01a
Timing of TS diagnosis (n, %)
 Prenatally 2 (10.5) 0 .13
 Postnatally 17 (89.5) 24 (100)
Abbreviations: BMI = body mass index; TS = Turner syndrome.
aSignificant difference.
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